Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

Moore, Paul A., Zhang, Wenjun, Rainey, G. Jonah, Burke, Steve, Li, Hua, Huang, Ling, Gorlatov, Sergey, Veri, Maria Concetta, Aggarwal, Sudeepta, Yang, Yinhua, Shah, Kalpana, Jin, Linda, Zhang, Sunan, He, Leilei, Zhang, Tengfei, Ciccarone, Valentina, Koenig, Scott, Bonvini, Ezio, Johnson, Syd·2011·Blood

Abstract

We describe the application of a novel, bispecific antibody platform termed dual affinity retargeting (DART) to eradicate B-cell lymphoma through coengagement of the B cell–specific antigen CD19 and the TCR/CD3 complex on effector T cells. Comparison with a single-chain, bispecific antibody bearing identical CD19 and CD3 antibody Fv sequences revealed DART molecules to be more potent in directing B-cell lysis. The enhanced activity with the CD19xCD3 DART molecules was observed on all CD19-expressing target B cells evaluated using resting and prestimulated human PBMCs or purified effector T-cell populations. Characterization of a CD19xTCR bispecific DART molecule revealed equivalent potency with the CD19xCD3 DART molecule, demonstrating flexibility of the DART structure to support T-cell/B-cell associations for redirected T cell–killing applications. The enhanced level of killing mediated by DART molecules was not accompanied by any increase in nonspecific T-cell activation or lysis of CD19− cells. Cell-association studies indicated that the DART architecture is well suited for maintaining cell-to-cell contact, apparently contributing to the high level of target cell killing. Finally, the ability of the CD19xTCR DART to inhibit B-cell lymphoma in NOD/SCID mice when coadministered with human PBMCs supports further evaluation of DART molecules for the treatment of B-cell malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-09-306449

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 260

Metadata

Authors
Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., Shah, K., Jin, L., Zhang, S., He, L., Zhang, T., Ciccarone, V., Koenig, S., Bonvini, E., & Johnson, S.
Venue
Blood
Published
2011-04-28
Volume
117
Issue
17
Pages
4542-4551
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2086766201
Cited by
260
References
33
FWCI
5.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2010-09-306449
The paper
Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., Shah, K., Jin, L., Zhang, S., He, L., Zhang, T., Ciccarone, V., Koenig, S., Bonvini, E., & Johnson, S. (2011). Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. https://doi.org/10.1182/blood-2010-09-306449

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.